[Edaily Reporter KIM SAE-MI ] Digital implant specialist DIO Corporation(039840)is expanding into overseas markets through the launch of new products and the development of an AI-based implant treatment platform.

DIO Corporation announced on the 20th that it has designated seven countries—China, Türkiye, Portugal, Mexico, Australia, India, and Russia—as key strategic markets and is pushing forward with expanding product supply and sales networks.

DIO Corporation’s consolidated revenue last year reached 164.1 billion won, a 37.1% increase from the previous year. Of this, implant exports totaled 126.7 billion won, an increase of more than 35 billion won year-over-year. Overseas revenue accounted for over 80% of the total.

In the first half of this year, the company recorded 54.3 billion won in revenue from these seven strategic countries. This accounts for more than 60% of total revenue. In particular, first-half revenue from Türkiye, Portugal, and India increased by an average of 40% compared to the same period last year.

By country, sales in China last year reached 42.3 billion won, an 82.3% increase from the previous year. Annual sales also exceeded 10 billion won in Türkiye (10.1 billion won), Portugal (10.3 billion won), and Mexico (10.1 billion won).

DIO Corporation aims to achieve sales growth of over 30% in its seven strategic countries. Its U.S. subsidiary also aims to surpass 10 billion won in sales this year and is pursuing entry into new markets such as Vietnam.

DIO Corporation is also increasing the supply of new products to expand its overseas market presence. Following the global launch of its “UNICON” and “SICON” implant systems this year, DIO Corporation plans to expand the supply of its new product, “PrismX,” to key markets by the end of the year.

PrismX is scheduled to see expanded distribution primarily in Australia, Mexico, the United States, Portugal, India, and Türkiye. DIO Corporation has also secured European Medical Device Regulation (MDR) certification for its three products: UNICON, SICON, and PrismX.

The company is also advancing the development of “DIO AX,” an AI-based implant treatment platform. DIO Corporation unveiled DIO AX at the global academic seminar “DIO International Meeting 2026” (DIM 2026), held on the 10th.

DIO AX is a platform that utilizes clinical data and AI technology to support healthcare professionals’ decision-making—from diagnostic data analysis to treatment planning, implant placement planning, and surgical guide design.

DIO Corporation plans to utilize more than 1.34 million clinical data points—accumulated over more than 10 years of operating its digital implant solution “DIO NAVI”—for the development of AI models. DIO AX is currently being developed in collaboration with #LG CNS.

The company plans to combine AI-based clinical support services with sales of its existing implant products through DIO AX to establish a new revenue model.

DIO Corporation stated, “We plan to expand implant sales in major overseas markets through new products, including Prism X,” adding, “We will also explore software business opportunities based on DIO AX that utilize clinical data and AI.”